Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation

Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old J...

Descripción completa

Detalles Bibliográficos
Autores principales: Makimoto, Go, Nishi, Tatsuya, Kawakado, Keita, Nishimura, Tomoka, Tamura, Tomoki, Kudo, Kenichiro, Kuyama, Shoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516312/
https://www.ncbi.nlm.nih.gov/pubmed/32461525
http://dx.doi.org/10.2169/internalmedicine.4429-20
_version_ 1783586980733386752
author Makimoto, Go
Nishi, Tatsuya
Kawakado, Keita
Nishimura, Tomoka
Tamura, Tomoki
Kudo, Kenichiro
Kuyama, Shoichi
author_facet Makimoto, Go
Nishi, Tatsuya
Kawakado, Keita
Nishimura, Tomoka
Tamura, Tomoki
Kudo, Kenichiro
Kuyama, Shoichi
author_sort Makimoto, Go
collection PubMed
description Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for >12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria.
format Online
Article
Text
id pubmed-7516312
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-75163122020-10-02 Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation Makimoto, Go Nishi, Tatsuya Kawakado, Keita Nishimura, Tomoka Tamura, Tomoki Kudo, Kenichiro Kuyama, Shoichi Intern Med Case Report Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for >12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria. The Japanese Society of Internal Medicine 2020-05-26 2020-09-01 /pmc/articles/PMC7516312/ /pubmed/32461525 http://dx.doi.org/10.2169/internalmedicine.4429-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Makimoto, Go
Nishi, Tatsuya
Kawakado, Keita
Nishimura, Tomoka
Tamura, Tomoki
Kudo, Kenichiro
Kuyama, Shoichi
Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
title Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
title_full Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
title_fullStr Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
title_full_unstemmed Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
title_short Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
title_sort successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the egfr t790m mutation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516312/
https://www.ncbi.nlm.nih.gov/pubmed/32461525
http://dx.doi.org/10.2169/internalmedicine.4429-20
work_keys_str_mv AT makimotogo successfuldesensitizationtreatmentwithosimertinibafterthedevelopmentofosimertinibinducedurticariainapatientundergoingtreatmentfornonsmallcelllungcancerharboringtheegfrt790mmutation
AT nishitatsuya successfuldesensitizationtreatmentwithosimertinibafterthedevelopmentofosimertinibinducedurticariainapatientundergoingtreatmentfornonsmallcelllungcancerharboringtheegfrt790mmutation
AT kawakadokeita successfuldesensitizationtreatmentwithosimertinibafterthedevelopmentofosimertinibinducedurticariainapatientundergoingtreatmentfornonsmallcelllungcancerharboringtheegfrt790mmutation
AT nishimuratomoka successfuldesensitizationtreatmentwithosimertinibafterthedevelopmentofosimertinibinducedurticariainapatientundergoingtreatmentfornonsmallcelllungcancerharboringtheegfrt790mmutation
AT tamuratomoki successfuldesensitizationtreatmentwithosimertinibafterthedevelopmentofosimertinibinducedurticariainapatientundergoingtreatmentfornonsmallcelllungcancerharboringtheegfrt790mmutation
AT kudokenichiro successfuldesensitizationtreatmentwithosimertinibafterthedevelopmentofosimertinibinducedurticariainapatientundergoingtreatmentfornonsmallcelllungcancerharboringtheegfrt790mmutation
AT kuyamashoichi successfuldesensitizationtreatmentwithosimertinibafterthedevelopmentofosimertinibinducedurticariainapatientundergoingtreatmentfornonsmallcelllungcancerharboringtheegfrt790mmutation

Ejemplares similares